Mesoblast Limited
MSB.ASXHealth Care
A biotechnology company in the area of adult stem cell technology.
Market Data
$2.140
+0.1%$2.8B
-100000.0x
$-0.103
0.00%
-0.1%
Latest Earnings
Half Year Report and Accounts (including Appendix 4D)
27 February 2026
Mesoblast achieved a significant inflection point with Ryoncil® product sales of $48.7M in the first six months following its late-March 2025 commercial launch, though the company recorded a net loss of $40.2M (vs $47.9M loss in pcp) on total revenues of $51.3M. The company secured $75M from a new $125M non-dilutive credit facility and maintains $130M in cash, providing runway to fund operations and continued commercialization despite elevated R&D and SG&A spend. Key points: Ryoncil® launched commercially in late March 2025 with $48.7M in product sales captured in just 3 months of the half-year period, demonstrating strong market acceptance; Net loss improved 16.3% to $40.2M vs $47.9M in pcp, with gross margin of 85.2% showing strong product economics; Secured $75M drawn from a new $125M non-dilutive credit facility with favourable terms; second $50M tranche available through June 2026
Recent Announcements
Becoming a substantial holder
State Street Corporation became a substantial holder (5.19%).
Corporate Presentation and Half Year Financial Results
Mesoblast Limited (ASX: MSB; Nasdaq: MESO) reported H1 FY26 financial results showing RYONCIL net revenue of US$49M following FDA approval in December 2024, with guidance of US$110-120M for full-year FY2026; the company maintains a strong cash position of US$130M and is advancing clinical programs for label expansions and second-generation products including rexlemestrocel-L.
Half Year Report and Accounts (including Appendix 4D)
Mesoblast achieved a significant inflection point with Ryoncil® product sales of $48.7M in the first six months following its late-March 2025 commercial launch, though the company recorded a net loss of $40.2M (vs $47.9M loss in pcp) on total revenues of $51.3M. The company secured $75M from a new $125M non-dilutive credit facility and maintains $130M in cash, providing runway to fund operations and continued commercialization despite elevated R&D and SG&A spend. Key points: Ryoncil® launched commercially in late March 2025 with $48.7M in product sales captured in just 3 months of the half-year period, demonstrating strong market acceptance; Net loss improved 16.3% to $40.2M vs $47.9M in pcp, with gross margin of 85.2% showing strong product economics; Secured $75M drawn from a new $125M non-dilutive credit facility with favourable terms; second $50M tranche available through June 2026
Earnings Release - 26 February 2026
Upcoming earnings release expected 26 February 2026 (from Yahoo Finance (confirmed))
Mesoblast 2026 Half Year Financial Results Webcast
This is an announcement of an upcoming webcast for Mesoblast's half-year financial results ending December 31, 2025, scheduled for February 26-27, 2026. The announcement does not contain any actual financial results or metrics, only webcast details and company background information. No financial performance or outlook can be assessed from this preliminary announcement. Key points: Ryoncil is the first FDA-approved mesenchymal stromal cell therapy for pediatric SR-aGvHD; Strong intellectual property portfolio with over 1,000 granted patents extending to at least 2044; Established commercial partnerships in Japan, Europe and China
Get real-time alerts for MSB
Receive AI-powered earnings summaries and instant notifications when Mesoblast Limited releases results.
Register Free